Literature DB >> 8148223

The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate.

P J Hayball1, J Wrobel, J G Tamblyn, R L Nation.   

Abstract

A single dose of racemic ketorolac (30 mg of tromethamine salt, Toradol) was administered by bolus intramuscular injection to four young, healthy volunteers. The concentrations of total (bound plus unbound) (R)- and (S)-ketorolac were measured in plasma for 9 h after dosing. The mean +/- s.d. clearance of (S)-ketorolac (45.9 +/- 10.1 ml h-1 kg-1) exceeded (P = 0.0032) that of the (R)-enantiomer (19.0 +/- 5.0 ml h-1 kg-1). The mean +/- s.d. AUC ratio for (S)-ketorolac:(R)-ketorolac (0.442 +/- 0.043) was significantly different from unity (P = 0.0001). The steady-state volume of distribution of (S)-ketorolac (0.135 +/- 0.022 l kg-1) was significantly different (P = 0.0013) from that of its optical antipode (0.075 +/- 0.014 l kg-1) and the half-lives of (S)- and (R)-ketorolac (2.35 +/- 0.23 h and 3.62 +/- 0.79 h, respectively) were also significantly different (P = 0.026). These data indicate that the disposition of ketorolac in man is subject to marked enantioselectivity and, because of possible differences in biological activity of (S)- and (R)-ketorolac, emphasize the need to monitor separate stereoisomer concentrations of the drug if pharmacological data are to be interpreted correctly.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8148223      PMCID: PMC1364714          DOI: 10.1111/j.1365-2125.1994.tb04243.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

Review 2.  Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism?

Authors:  H Spahn-Langguth; L Z Benet
Journal:  Drug Metab Rev       Date:  1992       Impact factor: 4.518

3.  Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tromethamine.

Authors:  D Jung; E J Mroszczak; A Wu; T L Ling; H Sevelius; L Bynum
Journal:  Pharm Res       Date:  1989-01       Impact factor: 4.200

4.  Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration.

Authors:  D Jung; E Mroszczak; L Bynum
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

6.  The analgesic and anti-inflammatory profile of (+/-)-5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2a]pyrrole-1-carboxylic acid (RS-37619).

Authors:  W H Rooks; A J Tomolonis; P J Maloney; M B Wallach; M E Schuler
Journal:  Agents Actions       Date:  1982-12

7.  Stereoselective analysis of ketorolac in human plasma by high-performance liquid chromatography.

Authors:  P J Hayball; J G Tamblyn; Y Holden; J Wrobel
Journal:  Chirality       Date:  1993       Impact factor: 2.437

8.  Pharmacokinetics of single-dose oral and intramuscular ketorolac tromethamine in the young and elderly.

Authors:  N S Jallad; D C Garg; J J Martinez; E J Mroszczak; D J Weidler
Journal:  J Clin Pharmacol       Date:  1990-01       Impact factor: 3.126

9.  Absolute configuration of (-)-5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2-alpha]pyrrole-1-carboxylic acid, the active enantiomer of ketorolac.

Authors:  A Guzmán; F Yuste; R A Toscano; J M Young; A R Van Horn; J M Muchowski
Journal:  J Med Chem       Date:  1986-04       Impact factor: 7.446

10.  Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans.

Authors:  E J Mroszczak; F W Lee; D Combs; F H Sarnquist; B L Huang; A T Wu; L G Tokes; M L Maddox; D K Cho
Journal:  Drug Metab Dispos       Date:  1987 Sep-Oct       Impact factor: 3.922

View more
  8 in total

Review 1.  Chirality and nonsteroidal anti-inflammatory drugs.

Authors:  P J Hayball
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 2.  Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management.

Authors:  J C Gillis; R N Brogden
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

3.  Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics.

Authors:  Pyry A Välitalo; Heidi Kemppainen; Aida Kulo; Anne Smits; Kristel van Calsteren; Klaus T Olkkola; Jan de Hoon; Catherijne A J Knibbe; Karel Allegaert
Journal:  Br J Clin Pharmacol       Date:  2017-05-14       Impact factor: 4.335

4.  Ketorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months.

Authors:  Anne M Lynn; Heidi Bradford; Eric D Kantor; Marilee Andrew; Paolo Vicini; Gail D Anderson
Journal:  Paediatr Anaesth       Date:  2010-12-29       Impact factor: 2.556

5.  A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients.

Authors:  Yuna Guo; S Ray Kenney; Linda Cook; Sarah F Adams; Teresa Rutledge; Elsa Romero; Tudor I Oprea; Larry A Sklar; Edward Bedrick; Charles L Wiggins; Huining Kang; Lesley Lomo; Carolyn Y Muller; Angela Wandinger-Ness; Laurie G Hudson
Journal:  Clin Cancer Res       Date:  2015-06-12       Impact factor: 12.531

6.  Enantiomer-specific ketorolac pharmacokinetics in young women, including pregnancy and postpartum period.

Authors:  Aida Kulo; Anne Smits; Sanita Maleškić; Marc Van de Velde; Kristel Van Calsteren; Jan De Hoon; Rene Verbesselt; Jan Deprest; Karel Allegaert
Journal:  Bosn J Basic Med Sci       Date:  2017-02-21       Impact factor: 3.363

7.  The problem of racemization in the stereospecific assay and pharmacokinetic evaluation of ketorolac in human and rats.

Authors:  M Vakily; B Corrigan; F Jamali
Journal:  Pharm Res       Date:  1995-11       Impact factor: 4.200

Review 8.  Etodolac clinical pharmacokinetics.

Authors:  D R Brocks; F Jamali
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.